icddr,b: How a Dhaka Cholera Laboratory Changed Global Medicine

In the Mohakhali area of Dhaka stands an institution much of the city knows simply as “the cholera hospital”. Its formal name is the International Centre for Diarrhoeal Disease Research, Bangladesh — written, in its own preferred style, as icddr,b. It began in December 1960 as a small laboratory created by a Cold War military alliance to study a single disease. It became something far larger: the institution that proved oral rehydration therapy, keeper of some of the longest-running health records anywhere on earth, and a hospital system that treats well over a hundred thousand patients a year, almost all of them poor, without charge. Few research institutions based in a low-income country have changed the daily practice of medicine around the world as profoundly as this one.

A Laboratory for Cholera: 1960

The laboratory was born of geopolitics as much as of medicine. In 1960 the South East Asian Treaty Organization (SEATO), the Western alliance formed to contain communism in Asia, agreed with the United States and Pakistan to fund serious research on cholera, a disease that threatened soldiers and civilians alike across the region. On 5 December 1960, just as the seventh cholera pandemic was beginning in Asia, the Cholera Research Laboratory opened in Dhaka, then the capital of Pakistan’s eastern province, to be operated under the US National Institutes of Health. Its first director was Fred Soper, a veteran American epidemiologist; after Soper and his successor Abram Benenson, the laboratory passed in 1965 to Robert Allan Phillips, a US Navy physician who had spent years measuring what cholera does to the human body.

That measurement was the laboratory’s first great contribution. Cholera kills not by destroying tissue but by volume: the toxin forces the intestine to pour out fluid, and an untreated patient can die of dehydration within hours, with case fatality rates of 30 to 50 per cent. Phillips’s teams placed patients on cholera cots and measured everything — every millilitre drunk or infused, every millilitre lost — until they knew the precise composition and speed of the losses. From those balance studies came intravenous regimens matched exactly to what the body was losing, standardised in Dhaka as the “5:4:1” solution of salts and bicarbonate. By 1966, the laboratory’s own records show, cholera case fatality in its care had fallen below one per cent, and the Dhaka Hospital it had opened in 1962 was saving nearly everyone who reached it in time.

But intravenous therapy had hard limits. It needed sterile fluid, needles, tubing and trained staff, delivered fast — exactly what rural Bengal, and most of the poor world, did not have when an epidemic struck a village. The laboratory had proved cholera need not kill. The question that defined its next decade was whether the rescue could be taken out of the hospital.

The Discovery That Mattered: Oral Rehydration

The scientific key was a piece of physiology established in the 1950s: in the small intestine, the absorption of glucose is coupled to the absorption of sodium, and water follows. Crucially, cholera does not destroy this machinery — even in the worst of the disease, a solution of glucose and salts, drunk by the patient, is pulled across the gut wall. There had been a lonely foreshadowing. In Calcutta in 1953, Hemendra Nath Chatterjee reported in The Lancet that he had rehydrated 186 cholera patients with an oral salt-and-glucose solution, controlling their vomiting with an antihistamine. Without controls or measured fluid balances, his paper convinced almost no one, and it sank from view.

In Dhaka the proof was assembled piece by piece. Phillips himself had tried oral glucose solution during a Philippine outbreak in 1961, inconclusively. In 1967–68, researchers at the laboratory — among them Norbert Hirschhorn, whose perfusion studies showed glucose solutions cutting stool losses, and two young American physicians, David Nalin and Richard Cash, working with Bangladeshi colleagues Rafiqul Islam and Majid Molla — turned the physiology into a protocol: give the patient an oral glucose–electrolyte solution in volumes matched to what he was losing. In April 1968, in the laboratory’s hospital, they showed it worked in adults with severe cholera, maintaining hydration while cutting the need for intravenous fluid by about 80 per cent. The results appeared in The Lancet that August. A field protocol then proved the same thing in the villages around Matlab Bazaar, where there were no drip stands at all.

Acceptance was slower than the science. Through the 1970s oral rehydration was extended to children and to non-cholera diarrhoea, and in 1978 The Lancet’s editors delivered the verdict that has followed it ever since, calling oral rehydration therapy “potentially the most important medical advance of this century”. That year the World Health Organization built its global diarrhoeal disease control effort around it. In Bangladesh, the therapy moved from clinics into homes: from 1980, BRAC’s Oral Therapy Extension Programme taught mothers door to door how to mix salt, sugar and water, reaching more than 12 million households in a decade — the journey traced in Wiki Bangla’s profile of BRAC. How many lives oral rehydration has saved cannot be counted exactly, but the estimates converge on an extraordinary scale: icddr,b’s leadership has put the figure at around 50 million lives, other assessments at 54 million or more, and a 2024 review at roughly 70 million.

War and Refugees: 1971

In 1971 the laboratory’s science was tested in catastrophe — and the laboratory itself nearly destroyed. Bangladesh’s Liberation War drove an estimated eight to ten million refugees into India, and cholera exploded in the camps along the border, killing about 30 per cent of those it struck where treatment meant intravenous fluid that barely existed. In Dhaka, meanwhile, the Cholera Research Laboratory was crippled: most of its foreign staff were gone, the funding that had flowed through Islamabad stopped, and work shrank to a skeleton of its former scale.

The decisive demonstration happened across the border, at Bongaon in West Bengal, where Dilip Mahalanabis, a paediatrician from the Johns Hopkins centre in Calcutta who had followed the Dhaka work, ran a treatment centre for a camp population of some 350,000 people. When the intravenous fluid ran out, Mahalanabis made a judgement that orthodox medicine had resisted: he had oral rehydration salts pre-packed and administered not by doctors but by patients’ own families. Between late June and the end of August 1971 his centre treated 3,703 cholera patients and lost 135 — a case fatality of 3.6 per cent, and just 1 per cent in its demonstration unit, against the roughly 30 per cent dying elsewhere. A visiting WHO official, Dhiman Barua, carried the lesson back into the World Health Organization and UNICEF. When the results were published in 1973, sceptics initially found them hard to believe; they were, nonetheless, the proof at population scale that a drink of salt, sugar and water could defeat cholera anywhere. In 2006, Cash, Nalin and Mahalanabis shared the Prince Mahidol Award in Public Health for the discovery and its introduction.

Reinvention as icddr,b

Survival, for the Dhaka laboratory, was the achievement of the 1970s. A bilateral agreement brought American funding directly from Bangladesh’s side, but the structure was fragile, and when SEATO itself was dissolved in 1977 the laboratory lost the framework that had created it. Its future was openly in question.

The rescue was institutional. In 1978, following a proposal by an international group of scientists, the Government of Bangladesh issued an ordinance transforming the Cholera Research Laboratory into an independent international centre — the International Centre for Diarrhoeal Disease Research, Bangladesh. Its charter, negotiated with the government, was accepted at a meeting hosted by the World Health Organization in Geneva in 1979, and Bangladesh’s parliament ratified the settlement the same year, chartering the centre to work on diarrhoeal diseases and the related fields of nutrition and fertility. A grant from the Ford Foundation helped underwrite the transition. The renamed institution — soon universally shortened to icddr,b — was governed by an international board, funded by many governments rather than one alliance, and mandated to look beyond cholera alone. It was, in effect, the laboratory refounded as a permanent institution of the country it stood in.

Matlab: The Village Laboratory

If the Dhaka hospital is icddr,b’s heart, Matlab is its memory. In 1963 the laboratory opened a field station in Matlab, a riverine subdistrict south-east of Dhaka, initially to test cholera vaccines. To know whether a vaccine worked, researchers needed to know exactly who lived, was born, fell ill, migrated and died in the study villages — so in 1966 they began continuous demographic surveillance, registering every birth, death and move in the population. The system never stopped. Covering about 142 villages and more than 230,000 people, Matlab’s Health and Demographic Surveillance System has run for some six decades and stands among the longest-running and richest longitudinal health records in the developing world.

Matlab’s design — measured populations, a treatment area and a comparison area side by side — let icddr,b answer questions almost no one else could. From 1977, its Maternal and Child Health–Family Planning project delivered intensive doorstep contraceptive and child-health services to half the surveillance area; fertility and child deaths fell markedly faster there than in the comparison half, and in 1982 the findings were handed to the Government of Bangladesh, helping to shape the national family planning programme. The same platform hosted the village trials of oral rehydration, the vaccine studies described below, and the community trial that established zinc as a treatment for childhood diarrhoea. The Matlab Hospital, with 120 beds inside the surveillance area, treats more than 30,000 people a year, free — the field station is a working health service as well as a laboratory, which is precisely why its data carries such weight.

Beyond Cholera: Vaccines, Zinc and Child Survival

The institution built in 1978 set out to be more than the home of one therapy, and its record since is a series of answers to the diseases that actually kill poor children. Vaccines came first. The injectable cholera vaccines tested at Matlab in the 1960s had failed, so in January 1985 icddr,b, with the government and WHO, launched one of the largest vaccine field trials of its era: 63,498 children and women in Matlab received three doses of a killed oral cholera vaccine, with or without the toxin’s B subunit, or a placebo. The B-subunit vaccine protected 85 per cent of recipients in the first six months; over three years both vaccines held at about 50 per cent, and later analysis showed unvaccinated neighbours were protected too — herd immunity in action. That lineage led, by way of technology transfer, to Shanchol, the first affordable oral cholera vaccine, prequalified by WHO in 2011, and to the global vaccine stockpile WHO created in 2013. icddr,b kept working the problem in Dhaka itself, testing how the vaccine could be introduced in the slums of Mirpur and showing that even a single dose protected Bangladeshi adults.

The same trial machinery served other vaccines. In a cluster-randomised study across 142 Matlab villages between 2008 and 2011, two doses of the live rotavirus vaccine Rotarix given at six and ten weeks of age cut rotavirus diarrhoea among vaccinated infants by about 41 per cent — the first prospective evidence from Asia that the WHO-recommended schedule worked in a poor, high-burden setting. Zinc followed from Matlab too: a community trial led by Abdullah Baqui showed that children given zinc with each diarrhoea episode recovered faster and died substantially less often; in 2004 WHO and UNICEF added ten to fourteen days of zinc to their diarrhoea guidelines, and icddr,b’s SUZY project then mounted the world’s first national scale-up of zinc treatment, complete with a dispersible “Baby Zinc” tablet made with Bangladeshi manufacturers. Beyond diarrhoea, the centre’s protocolised care for severely malnourished children, published in The Lancet in 1999, cut hospital deaths from about 20 per cent to under 5 per cent; it has researched pneumonia since the late 1980s, and in 2001 opened what it records as Bangladesh’s first tuberculosis laboratory, its work feeding into national guidelines on childhood TB and malnutrition alike.

icddr,b Today

The institution that stands at Mohakhali today is an unusual hybrid: a research institute, a university-grade training centre and a working hospital for the poor, at 68 Shaheed Tajuddin Ahmed Sarani in Dhaka. Its Dhaka Hospital, opened in 1962 and described by the institute as the world’s largest diarrhoeal disease hospital, treats more than 140,000 patients a year, expanding with tents and extra cots in epidemic surges — and charges none of them anything. Around 4,000 staff work across the Dhaka campus, Matlab and other field sites, governed by a 17-member multinational Board of Trustees and supported by about 55 donor countries and organisations, among them the governments of Bangladesh, Canada, Sweden, the United Kingdom and the United States. Since February 2021 the executive director has been Dr Tahmeed Ahmed, a nutrition scientist who joined in 1985 and is the first Bangladeshi to hold the post; the centre now operates under the icddr,b Act 2022, its modern charter from Bangladesh’s parliament. Its scientists still deploy abroad when cholera strikes — teams went to Pakistan and Haiti in 2010 — and in 2020 the institute turned its laboratories and hospital to COVID-19, becoming one of Dhaka’s main testing and treatment centres. By its count, it has trained more than 27,000 health professionals from over 78 countries since 1978.

The honours have followed the results. In 2001 icddr,b received the first Gates Award for Global Health, for oral rehydration. In 2017 it won the Conrad N. Hilton Humanitarian Prize, then worth two million dollars and regarded as the world’s largest annual humanitarian award, for what the jury called its innovative approach to solving the health problems of the world’s most impoverished communities.

Conclusion

icddr,b’s history is a double argument. The first is about science: that the deadliest problems of poor places can be solved by rigorous research done in those places, by people willing to measure a cholera patient’s losses litre by litre until the treatment follows. Oral rehydration — pennies’ worth of salt and sugar — emerged from that discipline and has saved tens of millions of lives. The second argument is institutional: a laboratory founded by a military alliance for strategic reasons survived a war, the collapse of its patron and repeated funding crises, and was deliberately rebuilt, in 1978–79, as an international centre owned by no single country and anchored in Bangladesh. Six decades on, the cholera hospital at Mohakhali still treats whoever arrives, free — while the knowledge produced there quietly shapes how the whole world treats its sickest children.